Moreover, ROC analysis revealed that NEDD4L expression may be served as a potential biomarker for distinguishing ND-AML from CR-AML with an AUC value of 0.645 (95% confidence interval: 0.532–0.758, P = 0.017, Fig. 2b). Here, NEDD4L is linked to acute myeloid leukemia.